CROss Alliance® is the brand name for CROSS Research SA, a private Swiss Contract Research Organization (CRO) active in the field of clinical drug development. The group was founded in 1996 with an high specialisation in Phase I studies and early drug development; today the group staff accounts for 38 units and manages clinical trials from Phase I to Phase II-III in Swiss and EU clinical sites. With a portfolio of more than 500 clinical studies performed both in healthy volunteers and patients, CROss Alliance team has built “on the field” a deep knowledge of several clinical areas, among them: Anaesthesiology, Bioavailability studies, Cardiac safety, Central Nervous System, Dermatology, Gastroenterology and Pain. While the HQ is located in Mendrisio, CROSS Research SA has its Phase I Unit in Arzo (Canton Ticino), in a 825sqm facility equipped with 26 beds. In this independent building, Phase I studies are carried out in healthy volunteers and special populations with the aim of assessing drug safety, kinetics and disposition, establishing kinetic-dynamic relationships, measuring drug time-course of action in order to propose proper therapeutic dose regimens and fulfil the regulatory requests. The whole activity of data management, biostatistics and PK analysis are based on international guidelines and are performed following CROss Alliance and/or Sponsor's quality requirements and specific SOPs. CROss Alliance Team aims to provide its Customers with the highest possible quality services in the clinical development of drugs, never forgetting the commitment of safeguard of subjects and patients health every single day.